ArticleJournal of inflammation research2025
Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Changes in Complement Proteins in the Aqueous Humor and Plasma of Patients Undergoing Ranibizumab Treatment for Retinal Vein Occlusion: A Need for Further Research [Letter].Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. The concentrations of 13 complement proteins and vascular endothelial growth factor A (VEGF-A) were measured using Luminex Results: During ranibizumab treatment, a reduction in the levels of C1q (p < 0.001), C2 (p = 0.030), C4 (p = 0.001), C4b (p = 0.026), C3b/iC3b (p < 0.001), C5 (p = 0.007), C5a (p = 0.005), CFD (p = 0.022), CFH (p < 0.001), and CFI (p < 0.001) in AH was observed. No significant changes were observed in the plasma levels of all measured factors. At baseline, CRVO had higher levels of C4 (p = 0.003), C4b (p < 0.001), C3b/iC3b (p < 0.001), C5 (p = 0.020), C5a (p = 0.007), CFD (p = 0.002), CFH (p < 0.001), and CFI (p < 0.001) in AH compared to BRVO. Conclusion: Ranibizumab treatment reduced the intraocular but not circulating activation of classical and alternative complement pathways in RVO patients. Differences in intraocular complement proteins were observed between BRVO and CRVO patients, which may reflect different pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.